carbapenems has been researched along with Pulmonary Consumption in 4 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (25.00) | 29.6817 |
| 2010's | 3 (75.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ahmad, N; Ahuja, SD; Akkerman, OW; Alffenaar, JC; Anderson, LF; Baghaei, P; Bang, D; Barry, PM; Bastos, ML; Behera, D; Benedetti, A; Bisson, GP; Boeree, MJ; Bonnet, M; Brode, SK; Brust, JCM; Cai, Y; Caumes, E; Cegielski, JP; Centis, R; Chan, ED; Chan, PC; Chang, KC; Charles, M; Cirule, A; D'Ambrosio, L; Dalcolmo, MP; de Vries, G; Dheda, K; Esmail, A; Flood, J; Fox, GJ; Fréchet-Jachym, M; Fregona, G; Gayoso, R; Gegia, M; Gler, MT; Gu, S; Guglielmetti, L; Holtz, TH; Hughes, J; Isaakidis, P; Jarlsberg, L; Kempker, RR; Keshavjee, S; Khan, FA; Kipiani, M; Koenig, SP; Koh, WJ; Kritski, A; Kuksa, L; Kvasnovsky, CL; Kwak, N; Lan, Z; Lange, C; Laniado-Laborín, R; Lee, M; Leimane, V; Leung, CC; Leung, EC; Li, PZ; Lowenthal, P; Maciel, EL; Marks, SM; Mase, S; Mbuagbaw, L; Menzies, D; Migliori, GB; Milanov, V; Miller, AC; Mitnick, CD; Modongo, C; Mohr, E; Monedero, I; Nahid, P; Ndjeka, N; O'Donnell, MR; Padayatchi, N; Palmero, D; Pape, JW; Podewils, LJ; Reynolds, I; Riekstina, V; Robert, J; Rodriguez, M; Schnippel, K; Seaworth, B; Seung, KJ; Shim, TS; Singla, R; Smith, SE; Sotgiu, G; Sukhbaatar, G; Tabarsi, P; Tiberi, S; Trajman, A; Trieu, L; Udwadia, ZF; van der Werf, TS; Veziris, N; Viiklepp, P; Vilbrun, SC; Walsh, K; Westenhouse, J; Yew, WW; Yim, JJ; Zetola, NM; Zignol, M | 1 |
| Doi, N; Horita, Y; Kazumi, Y; Maeda, S | 1 |
| Nuermberger, EL; Spigelman, MK; Yew, WW | 1 |
| Hashimoto, K; Ito, K; Ogata, H | 1 |
2 review(s) available for carbapenems and Pulmonary Consumption
| Article | Year |
|---|---|
Treatment correlates of successful outcomes in pulmonary multidrug-resistant tuberculosis: an individual patient data meta-analysis.
Topics: Amikacin; Antitubercular Agents; Capreomycin; Carbapenems; Clofazimine; Diarylquinolines; Drug Therapy, Combination; Fluoroquinolones; Humans; Kanamycin; Levofloxacin; Linezolid; Moxifloxacin; Recurrence; Treatment Failure; Tuberculosis, Multidrug-Resistant; Tuberculosis, Pulmonary | 2018 |
Current development and future prospects in chemotherapy of tuberculosis.
Topics: Adamantane; Animals; Antitubercular Agents; Carbapenems; Clinical Trials as Topic; Diarylquinolines; Drug Delivery Systems; Ethylenediamines; Fluoroquinolones; Humans; Isonicotinic Acids; Mice; Mycobacterium tuberculosis; Nitroimidazoles; Oxazolidinones; Patient Compliance; Pyrroles; Quinolines; Rifamycins; Tuberculosis, Pulmonary | 2010 |
2 other study(ies) available for carbapenems and Pulmonary Consumption
| Article | Year |
|---|---|
In vitro susceptibility of Mycobacterium tuberculosis isolates to an oral carbapenem alone or in combination with β-lactamase inhibitors.
Topics: Antitubercular Agents; beta-Lactamase Inhibitors; Carbapenems; Drug Combinations; Drug Resistance, Multiple, Bacterial; Humans; Microbial Sensitivity Tests; Mycobacterium tuberculosis; Tuberculosis, Multidrug-Resistant; Tuberculosis, Pulmonary | 2014 |
[Activity of cephems and carbapenems against clinically isolated Mycobacterium abscessus].
Topics: Carbapenems; Cefoxitin; Ceftazidime; Cephalosporins; Drug Resistance, Bacterial; Humans; Imipenem; Meropenem; Microbial Sensitivity Tests; Mycobacterium chelonae; Mycobacterium Infections, Nontuberculous; Thienamycins; Tuberculosis, Pulmonary | 2003 |